Quentin Hill: UK Will Have Access to Generic Eltrombopag
Quentin Hill, Honorary Clinical Associate Professor at University of Leeds, shared a post on LinkedIn:
“From October 2025, the UK will have access to generic eltrombopag. Eltrombopag is one of three thrombopoietin receptor agonists (TPO RA) that are licenced treatments for immune thrombocytopenia (ITP).
While these treatments are not identical, their effectiveness is broadly similar and greater use of generic eltrombopag will result in a substantial, multi-million-pound, cost saving to the NHS.
In a joint position statement, the UK ITP Forum and UK ITP Support Association have recommended generic eltrombopag as the preferred initial TPO RA for use second line in ITP. However patients currently stabilised/established on a different TPO RA should continue with their treatment, and access to alternative NICE approved TPO RA (romiplostim, avatrombopag) should continue.”
The full published position statement can be found here.
Stay updated with Hemostasis Today.
-
Sep 1, 2026, 18:13Ramsha Batool: Chemotherapy-Induced Anemia Impacts Quality of Life in Breast Cancer
-
Sep 1, 2026, 18:09Natalya Shynhera: Using Anemia to Teach Medical English in Real Clinical Practice
-
Sep 1, 2026, 18:06Wei Du: New Therapeutic Potential for PARP Inhibitors in MLL-Rearranged Leukemia
-
Sep 1, 2026, 18:03Tobias Tichelbäcker: PRAGUE-26 Shows Catheter Lysis Beats Anticoagulation Without Ultrasound
-
Sep 1, 2026, 18:00Baptiste Thibault: My First Publication as First Author on Ionized Calcium Monitoring Before Citrate-CRRT
-
Sep 1, 2026, 17:51Nadezhda Vasilyeva: Shifting the Boundaries of Acute Ischemic Stroke Management
-
Sep 1, 2026, 17:49Malik Ghannam: Recent Venous Thrombosis Risk Factors May Help Explain Cryptogenic Stroke in Young Adults
-
Sep 1, 2026, 17:42Rishabh Jain: Renal Artery FMD Is Managed With Balloon Angioplasty Alone
-
Sep 1, 2026, 17:42Caitlin R: The Brain’s Need to Find Patterns